Medical device producer EMVision (ASX:EMV) has begun the second stage of a clinical trial for its portable brain scanning device.
EMVision said following the successful completion of Stage 1 with 30 healthy volunteers, 150 stroke patients will now be tested with the device in hospitals in Liverpool, Melbourne and Alexandra.
It also said data from Stage 1 helped improve the scanner's usability and workflow, and taught operators how to use the device more efficiently.
EMVision hopes the scanner will help provide quicker diagnoses and treatments for time-sensitive emergencies like strokes.